Non Executive Chair at Zentraxa - Start up biotech company developing novel, synthetic bio-polymers & bio-materials via a bespoke platform.Member of the Board & Executive team; development & nurturing of investor relations; mentoring/leadership in developing governance models; maximising both funding and commercial/JDA & licensing opportunities; development of strategic commercial proposition for target markets

Leading the conversation and driving innovation in clinical trials delivery.From trial design modelling in minutes, not days, that empowers faster & better recruitment to enrolment in an unparalleled trials platform with real time SAE monitoring & endpoint analysis.Discovering more. Delivering better.

Biotech, medical devices, pharma, healthcare and pharma services M&A and post integration consulting , offering specialist support from confirmatory/bid Due Diligence to post acquisition planning and delivery.

Interim Business Leader & Non-Executive Director (NED) - enterprising & commercially-led, with extensive experience of developing value-driven strategies to deliver large-scale transformational change and success.Internationally-experienced - having engaged across consulting, FMCG, pharmaceutical & corporate sectors.Collaborative approach to strategic business direction - engaging with senior stakeholders, investors and senior executives at up to C-level to build business plans, strategies, operating models and realise growth. Inspiring as a Business Leader - leveraging an ‘open’ management style to effectively empower and enable multi-functional, high-performing teams of up to 2500+ staff across 20 countries globally, and diverse cultures. Experience of business development through global launches of 50+ FMCG, pharma, medical device and biotech products, and highly-successful leadership of a series of 30+ major M&A and JV licensing deals.Highly accomplished - able to lead and grow multinational businesses from £20m to £500m+ and effectively turnaround organisations to improve profitability, sustainable growth and overall EBDITDA performance.

Full P&L responsibility for MEA/India business unit. Sales, marketing, Finance/contracting/pricing, logistics, BD and distributor management. Geographic expansion planning (India, Africa, support to SE Asia) HECON strategy and project management.

Global commercial, Therapy development, Product development, MedEd, & BD strategy. Responsible for P&L, annual operating plan.

Haemodialysis product & market development strategy. Integration of Althin products post acquisition. Home Haemo strategy & support to technical development.